Anti-PD-1 antibody therapy for epithelial skin malignancies
M Ishii(Keio University), Takeru Funakoshi(Keio University), Takayuki Fusumae(Keio University), Yasunori Sato(Keio University), Keiji Tanese(Toho University), Kenji Kabashima(Agency for Science, Technology and Research), Mana Nishiguchi(Wakayama Medical University), Taku Fujimura(Tohoku University), Naoya Yamazaki, Yoshio Nakamura(Keio University), Ikuko Hirai(Keio University), Atsushi Otsuka(Kyoto University), Keitaro Fukuda, Tatsuya Takenouchi(Niigata Cancer Center Hospital), Yuki Yamamoto(Tokyo University of Agriculture and Technology), Masayuki Amagai(RIKEN Center for Integrative Medical Sciences), Kenji Yokota(International Research Center for Japanese Studies), Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Hiroshi Uchi(Kyushu University)
Cited by 24
Related Papers
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
|Frontiers in Oncology|2018|1.3k
Inflammation-free, gas-permeable, lightweight, stretchable on-skin electronics with nanomeshes
|Nature Nanotechnology|2017|1.1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586